Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMMU01R)

Drug Name
Heteroaryl-cyclopropylamine derivative 4 Drug Info
Synonyms PMID27019002-Compound-22c
Cross-matching ID
TTD Drug ID
DMMU01R

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Download the Complete Related Drug List
Drug(s) Targeting Lysine-specific histone demethylase 1 (LSD)
Drug Name Drug ID Indication ICD 11 Highest Status REF
IMG-7289 DML9AVG Acute myeloid leukaemia 2A60 Phase 2 [2]
CC-90011 DM0EDHJ Lymphoma 2A80-2A86 Phase 2 [2]
CC-90011 DM0EDHJ Lymphoma 2A80-2A86 Phase 2 [3]
Vafidemstat DM64ZGY Alzheimer disease 8A20 Phase 2 [4]
ORY-2001 DMYM0UY Alzheimer disease 8A20 Phase 2 [5]
INCB59872 DMRLV7G Acute myeloid leukaemia 2A60 Phase 1/2 [2]
GSK2879552 DMT3V2W Small-cell lung cancer 2C25.Y Phase 1 [6]
Seclidemstat DMCP7SD Ewing sarcoma 2B52 Phase 1 [7]
TAS-1440 DMHIA7Y Acute myeloid leukaemia 2A60 Phase 1 [8]
Tarnylcypromine derivative 2 DMEJR2F N. A. N. A. Patented [1]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Lysine-specific demethylase 4A (KDM4A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
PMID25468267-Compound-46 DMSKCEH N. A. N. A. Patented [9]
N-(2-phenylcyclopropyl) amino acid derivative 1 DMH7T8C N. A. N. A. Patented [1]
PMID27019002-Compound-21b DMMC31N N. A. N. A. Patented [1]
Hydroxamate analog 1 DMGATHZ N. A. N. A. Patented [9]
PMID27019002-Compound-21c DMWZOKP N. A. N. A. Patented [1]
Disulfiram analog 1 DMOEFD3 N. A. N. A. Patented [9]
Selenium compound 2 DMLWIJ7 N. A. N. A. Patented [9]
Disulfiram analog 2 DMOMGU5 N. A. N. A. Patented [9]
Selenium compound 1 DM9C5Z8 N. A. N. A. Patented [9]
Selenium compound 3 DMQ5AJ6 N. A. N. A. Patented [9]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Lysine-specific demethylase 4A (KDM4A) TTZHPB8 KDM4A_HUMAN Inhibitor [1]
Lysine-specific histone demethylase 1 (LSD) TTNR0UQ KDM1A_HUMAN Inhibitor [1]

References

1 LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Discovery of CC-90011: A Potent and Selective Reversible Inhibitor of Lysine Specific Demethylase 1 (LSD1). J Med Chem. 2020 Dec 10;63(23):14522-14529.
4 Efficacy of Vafidemstat in Experimental Autoimmune Encephalomyelitis Highlights the KDM1A/RCOR1/HDAC Epigenetic Axis in Multiple Sclerosis. Pharmaceutics. 2022 Jul 6;14(7):1420.
5 Clinical pipeline report, company report or official report of Oryzon Genomics Boston, MA
6 A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC. Cancer Cell. 2015 Jul 13;28(1):57-69.
7 Scaffolding LSD1 Inhibitors Impair NK Cell Metabolism and Cytotoxic Function Through Depletion of Glutathione. Front Immunol. 2020 Sep 17;11:2196.
8 Clinical pipeline report, company report or official report of Astex Pharmaceuticals.
9 KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44.